⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279139 | 1.00 | — | — | |
| SCHEMBL17279141 | 1.00 | — | — | |
| SCHEMBL15135177 | 0.86 | — | — | |
| SCHEMBL15135179 | 0.86 | — | — | |
| SCHEMBL368612 | 0.84 | — | — | |
| SCHEMBL7016304 | 0.78 | — | — | |
| SCHEMBL1307793 | 0.75 | — | — | |
| SCHEMBL1414466 | 0.75 | — | — | |
| SCHEMBL1303273 | 0.75 | — | — | |
| SCHEMBL209083 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | claimed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | claimed |
| WO-2023175185-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175185-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| EP-1517907-A2 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | Sanofi-Aventis (FR) | 2005-03-30 | — | — | EP | disclosed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | disclosed |
| WO-2003106456-A2 | NEW COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2003-12-24 | — | — | WO | disclosed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | disclosed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | disclosed |